Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 655

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

Prof Pieter Sonneveld speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about results from the subgroup analysis of high risk patients in the CASSIOPEIA trial.

Prof Sonneveld explains that patients defined as 'high-risk' were those considered ISS stage 3 or having high-risk cytogenetics.

He reports that the stringent response and complete response of the high-risk patients was comparable to the standard group of patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation